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Identification of bacterial biofilm 
and the Staphylococcus aureus 
derived protease, staphopain, on 
the skin surface of patients with 
atopic dermatitis
Andreas Sonesson1,2, Kornelia Przybyszewska1,3,10, Sigrid Eriksson1,2, Matthias Mörgelin4, 
Sven Kjellström5, Julia Davies6, Jan Potempa3,7,8 & Artur Schmidtchen1,2,9
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by an impaired epidermal 
barrier, dysregulation of innate and adaptive immunity, and a high susceptibility to bacterial 
colonization and infection. In the present study, bacterial biofilm was visualized by electron microscopy 
at the surface of AD skin. Correspondingly, Staphylococcus aureus (S. aureus) isolates from lesional 
skin of patients with AD, produced a substantial amount of biofilm in vitro. S. aureus biofilms showed 
less susceptibility to killing by the antimicrobial peptide LL-37 when compared with results obtained 
using planktonic cells. Confocal microscopy analysis showed that LL-37 binds to the S. aureus biofilms. 
Immuno-gold staining of S. aureus biofilm of AD skin detected the S. aureus derived protease staphopain 
adjacent to the bacteria. In vitro, staphopain B degraded LL-37 into shorter peptide fragments. Further, 
LL-37 significantly inhibited S. aureus biofilm formation, but no such effects were observed for the 
degradation products. The data presented here provide novel information on staphopains present in 
S. aureus biofilms in vivo, and illustrate the complex interplay between biofilm and LL-37 in skin of AD 
patients, possibly leading to a disturbed host defense, which facilitates bacterial persistence.
Atopic dermatitis (AD) is a chronic inflammatory skin disease usually starting in early childhood with a reported 
lifetime prevalence of 15–30% in children, whereas the corresponding figure for adults is 2–10%1, 2. The patho-
genesis of AD involves genetic factors as well as gene-environmental interactions. Several genes associated with 
skin barrier dysfunction, proteolytic activity, and the immune system are found to be associated with AD, and 
play a role in the etiology of the dysfunctional skin barrier and the immunological abnormalities found in AD 
skin. The disease is characterized by a relapsing course and the clinical presentations of AD are severe pruritus, 
xerosis, an increased transepidermal water loss, typically distributed eczema lesions in flexural areas, and recur-
rent cutaneous infections. Skin colonization by Staphylococcus aureus (S. aureus) is prevalent in AD, and seems to 
be promoted by skin barrier impairment3, 4. S. aureus bacteria play an important role in the pathogenesis of AD 
by secreting toxins, antigens, and proteases that interact with keratinocytes and various inflammatory cells, and 
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lead to dysregulation of skin hemostasis, which ultimately compromises the epidermal barrier5. In vivo, biofilms 
are the predominant bacterial mode of life and may contribute to the pathogenesis of various chronic infections 
such as periodontitis, orthopedic infections, and non-healing skin ulcers6. Moreover, biofilms have also been 
detected on the skin of AD patients, and may possibly contribute to the inflammatory process7–9. Biofilms are 
bacterial agglomerations attached to a surface and embedded in an extracellular matrix10. Formation of biofilm 
is a successful strategy that protects the bacteria from environmental danger, antimicrobial peptides (AMPs), 
antibiotics and phagocytosis11, 12, enabling chronic persistence in the host. An increasing number of S. aureus skin 
isolates are resistant to conventional antibiotics and today, there is an unmet need for novel strategies to effectively 
counteract skin infections.
Resident cells of the epidermis, such as the keratinocytes have evolved mechanisms to combat colonization 
by pathogenic bacteria. One crucial strategy utilized by the epidermal cells is to secrete AMPs13. AMPs constitute 
a part of the innate immune defense and are of fundamental importance, in particular in relation to the often 
observed bacterial colonization of AD skin lesions14. In general AMPs are small cationic peptides with hydropho-
bic properties that interact with the target microorganism, preferentially negatively charged structures of the bac-
terial membrane, and form pores that eventually causes lysis of the cell15. In human skin several AMPs have been 
identified and are considered essential effector molecules of innate immunity16. In some cases, truncated parts of 
AMPs are detected during skin inflammation. For example, fragments of the cathelicidin peptide LL-37, gener-
ated by cutaneous protease activity, have been described in skin diseases such as acne rosacea17, 18. Furthermore, 
S. aureus derived proteinases, such as aureolysin and V8 protease, have previously been shown to degrade the 
human AMP LL-3719. Along with aureolysin and V8, the cysteine proteases staphopain A (ScpA) and B (SspB) are 
additional major proteases secreted by S. aureus. SspB is known to contribute to bacterial virulence, whereas ScpA 
seems to have another unrelated function20. Interestingly, the presence of V8 protease and aureolysin has been 
observed in staphylococcal isolates from AD patients21. However, currently there is no information regarding the 
expression of staphopains in AD isolates.
The aim of this study was to investigate the in vitro biofilm production by S. aureus isolates, derived from skin 
lesions of AD patients. Furthermore we aimed to investigate if bacterial proteases, such as staphopains, are pres-
ent at the skin surface of these patients. Moreover, we wanted to study, in vitro, if these proteases degraded LL-37, 
an important innate defense molecule found in inflamed skin.
Results
Visualization of bacterial biofilm in lesional skin of patients with AD. Scanning electron micros-
copy (SEM) analysis of skin biopsies from S. aureus colonized lesional skin of AD patients demonstrated the 
presence of bacteria and bacterial biofilm at the skin surface. The results showed biofilm at structures identified in 
the stratum corneum composed of corneocytes, intricate extracellular matrix material, and bacteria. Moreover, 
it was also possible to visualize individual bacteria surrounded by extracellular matrix material between the cor-
neocytes (Fig. 1a–c). When biopsies of non-lesional skin derived from a non-infected AD patient (Supplementary 
Fig. S1a,b) and from lesional skin of three AD patients (with S. aureus verified skin colonization) (Supplementary 
Fig. S1c–h) were investigated using SEM, the results showed that lesional AD skin contained considerably more 
fibrin, extracellular material, and bacteria when compared to non-lesional skin. Next, an ex vivo model was 
used to quantify the presence of strongly adherent bacteria, representing bacterial biofilm in skin biopsies from 
patients with AD. The quantification of adherent bacteria was done by enumerating colony-forming units (CFU) 
per square centimetre of skin released after the biopsies were washed, vortexed and sonicated. The results showed 
that both weakly (median value 1.01 × 104 CFU/cm2) and strongly (median value 1.38 × 104 CFU/cm2) attached 
bacteria were present in the AD skin samples (Supplementary Fig. S1i).
Biofilm production by S. aureus isolates derived from skin of patients with AD. Biofilm for-
mation was measured among 32 isolates of S. aureus derived from skin of AD patients and molecular typing 
was performed using ADSRRS-fingerprinting analysis. The results showed that 12 out of 32 of the isolates 
Figure 1. The presence of bacterial biofilm at lesional AD skin colonized with S. aureus. Biofilm observed by 
scanning electron microscopy on the stratum corneum of an AD patient. (a) Microbial biofilm on skin of an AD 
patient colonized with S. aureus. The high magnification pictures in figures b and c are derived from the area 
in box b and c. Scale bar 100 μm. (b) Biofilm composed of intricate extracellular matrix material and bacteria. 
Scale bar 10 μm. (c) High magnification view visualizing individual bacteria surrounded by extracellular matrix 
material observed between corneocytes on AD skin. Scale bar 2 μm.
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(38%) have the ability to produce a substantial amount of biofilm in vitro, as detected using the crystal vio-
let method (Supplementary Table S1 and Supplementary Fig. S2). According to the molecular typing data, the 
capacity to produce biofilm was not associated with any specific strain among the skin-derived S. aureus isolates, 
(Supplementary Table S1). Notably, six of the isolates showed strong capacity to produce biofilm in vitro, yielding 
an OD600-value in the biofilm assay of more than 0.6 (Supplementary Fig. S2).
It has been recently shown by SEM that the organization of S. aureus bacteria undergo gradual morpho-
logical changes at different growth phases during biofilm formation22. To determine if the differences in bio-
film formation were dependent on the growth of the bacterial isolates, the optical density of liquid cultures was 
measured spectrophotometrically. The results showed that growth rates were approximately similar among 
the tested S. aureus strains (Supplementary Fig. S3), and no significant differences between strong and weak 
biofilm-producing strains were observed.
Antimicrobial effects of LL-37. To test if the human cathelicidin peptide LL-37 exerted different antimi-
crobial effects on planktonic bacteria and on bacterial biofilm, a modified version of the minimal biofilm erad-
ication concentration (MBEC) assay was used on various biofilm producing S. aureus isolates, all derived from 
skin of patients with AD. The results showed a marked difference between the minimum inhibitory concentration 
(MIC) values and the MBEC values, and indicated that the concentration of LL-37 needed to eradicate bacterial 
biofilms exceeded the highest tested concentration of 160 μM (Table 1). In contrast, the MIC values obtained for 
planktonic cells were in the range of 10–20 μM LL-37 (Table 1).
Visualization by confocal light scanning microscopy (CLSM) of human LL-37 binding to bacte-
rial biofilm. To determine whether LL-37 binds to the bacterial biofilm, mature (6-day old) biofilms produced 
by three S. aureus isolates, derived from lesional skin of three AD patients, were grown on CellviewTM cell culture 
dishes with glass bottom. The bacterial cells in the biofilm were stained with the fluorescent stain SYTO® 9 green 
and incubated with TAMRA labeled LL-37. The results showed that the LL-37 peptide bound to the bacterial 
cells in the biofilms (Fig. 2). When the Z-stacks were analyzed, and quantification of the intensity obtained by 
Profile plug-in (Zeiss ZEN Confocal Software), results indicated three distinctly different populations of fluoro-
phores in the samples; red (TAMRA labeled LL-37) and green (SYTO® 9) seen separately, and yellow representing 
co-existence of bacterial cells and the TAMRA-labeled LL-37 peptide. Binding of TAMRA labeled LL-37 to the S. 
aureus cells was observed throughout the biofilm (Supplementary Fig. S4a–c).
S. aureus staphopain and effects on LL-37. Previous investigations demonstrated that LL-37 could be 
degraded by the staphylococcal proteases aureolysin and V8 protease19. Here, we explored whether the S. aureus 
derived protease staphopain was produced by the bacteria in vivo and if it could cleave LL-37 in vitro. First, biop-
sies from lesional skin of patients with AD were examined using electron microscopy, with gold-labeled antibod-
ies against the protease. The results showed that the S. aureus staphopain was indeed present adjacent to coccoid 
bacteria in the biofilm (Fig. 3a,b). As SspB has been particularly associated with virulence20, we first investigated 
if this protease was able to degrade LL-37. As demonstrated by gel-electrophoresis, LL-37 was degraded into 
fragments of lower molecular weight by the enzyme. The digested material was analyzed by mass spectrome-
try (MS) and the results revealed several low molecular weight peptide fragments (Fig. 3c,d). Moreover, when 
LL-37 was subjected to ScpA the results did not reveal any obvious major cleavage of LL-37 as demonstrated by 
gel-electrophoresis, although the MS data detected cleavage of minor fragments (Supplementary Fig. S5). These 
data were thus in correspondence with previous findings of SspB as a major virulence factor.
To investigate the antibacterial effects of the peptide fragments on planktonic bacteria, a radial diffusion 
assay was performed. The results demonstrated that only one fragment, FKR21 was antimicrobial against the 
Gram-positive S. aureus and Gram-negative E. coli bacteria (Fig. 4a).
Fragments of LL-37 have previously been ascribed both pro-and anti-inflammatory effects23–29. Table 2 com-
pares the identified fragments with previously published LL-37 derived peptide sequences, and references are 
included illustrating reported immune-modulating actions. To explore if these staphopain-generated peptide 
fragments also showed immune-modulatory effects in vitro, four peptide sequences from the C-terminal part 
of LL-37 identified by MSMS were synthesized (FKR10, FLR11, LLG11 and FKR21) (Table 2 and Fig. 3d). The 
peptides were then added to lipopolycaccharide (LPS)- or lipoteichoic acid (LTA)-stimulated human monocytic 








13 E 0.89 (0.09) 10 >160
5 N 0.16 (0.04) 20 >160
3 S 0.20 (0.06) 10 >160
24 L 1.08 (0.11) 20 >160
ATCC 29213 NA 0.42 (0.09) 20 >160
Table 1. Measurement of the bacterial susceptibility to the AMP LL-37 was determined by using a modified 
version of the Calgary Biofilm Device (CBD) method59. Minimum Inhibitory Concentration (MIC) and 
Minimal Biofilm Eradication Concentration (MBEC) are assessed among two low and two high biofilm 
producing isolates derived from skin of patients with AD, as well as the ATCC strain 29213.
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Figure 2. LL-37 binding to bacterial biofilm. Three S. aureus isolates, derived from three patients with AD, were 
grown on CellviewTM cell culture dishes for 6 days to form mature biofilms. After washing away the planktonic 
cells, the bacterial cells of the biofilm (green) were stained with SYTO® 9 green fluorescent stain and then 
incubated with TAMRA-labeled LL-37 (red), co-existence of bacterial cells and the TAMRA-labeled LL-37 
peptide is represented by yellow color. CLSM orthogonal images of Z-stacks show a plane view (square) looking 
down the biofilm and side views through the biofilm (right and below). Magnification in (a) ×20, bar 20 μm, in 
(b) ×63, bar 10 μm and in (c) ×63, bars 10 μm and 5 μm. *3D view of the corresponding biofilms.
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Figure 3. The S. aureus derived protease staphopain in bacterial biofilm and degradation of LL-37. (a) 
Visualization of staphopain protease at the bacterial surface of cocci-like bacterial structures in skin biopsy from 
S. aureus colonized lesional skin of patient with AD. Binding of gold-conjugated antibodies, directed against the 
S. aureus derived proteases ScpA and SspB, are shown at the surface of coccoid bacteria. Scale bar 100 nm. (b) 
In the control experiments, no unspecific binding of gold-conjugated secondary IgG antibodies was observed, 
scale bar 100 nm. (c) LL-37 was incubated with and without S. aureus SspB and analysed using SDS-PAGE 
(Novex® 10–20% Tricine Gel). Several distinct low molecular weight fragments were observed and further 
analyzed by MS. (d) Mass spectrometry analysis (depicted in blue) of the proteolytic digested LL-37 by SspB, 
resulting in 100% sequence coverage. The arrows illustrate proteolytic cleavage sites, and MSMS experiment 
(depicted in red) on the 1–11 peptide resulted in an almost complete y- and b-ion series that identifies the 1–11 
sequence LLGDFFRKSKE. Moreover, the analysis revealed an additional fragment (LLG16) (lower panel).
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AP-1, central initiators of pro-inflammatory cytokine production30, 31. The results showed that that only FKR21 
dose-dependently reduced LPS- and LTA-induced NF-κB and AP-1 activation (Fig. 4b), the results of LL-37 are 
included for comparison (Fig. 4c). To investigate the impact on viability of keratinocytes, by the LL-37 derived 
peptide fragments, HaCaT cells were subjected to the fragments. The viability was analysed by utilizing the MTT 
Figure 4. Antimicrobial and immune-modulatory effects of LL-37 and peptide fragments. (a) Determination 
of antimicrobial activity (using radial diffusion assay, RDA) of the peptide fragments (FKR10, FLR11, LLG11 
and FKR21) and LL-37 (100 μM) against S. aureus ATCC29213 (black bars) and E. coli ATCC25922 (grey 
bars) (n = 6). The right panel illustrates two scanned examples of representative RDA gels visualizing the 
zones of clearance corresponding to the inhibitory effects of the peptides against S. aureus and E. coli after 
incubation at 37 °C for 18–24 h (C, control, buffer 10 mM Tris pH 7.4). (b) Evaluation of NF-κB/AP-1 activation 
in supernatants of THP1-X-Blue CD14 cells after stimulation with 100 ng/ml of E. coli LPS (left) or 1 μg/ml 
of S. aureus LTA (right) and increasing concentrations of FKR21. (c) Evaluation of NF-κB/AP-1 activation 
in supernatants of THP1-X-Blue CD14 cells after stimulation with 100 ng/ml of E. coli LPS and increasing 
concentrations of LL-37 are shown for comparison. (d) Cell viability of HaCaT keratinocytes was analysed 
using a MTT assay. The results are indicated as mean absorbance values after treatment by the LL-37 derived 
peptide fragments, which correspond to the amount of living cells, and are compared to the control representing 
non-treated (NT) cells. Lysis Buffer (LB) yielded 100% lysis of the cells, mean values and SD of at least three 
independent experiments are presented (**P < 0.01, ***P < 0.001).
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assay. As shown, the HaCaT cells were not significantly affected by the LL-37 derived peptide fragments (Fig. 4d). 
It is of note that the analysis also revealed an additional minor fragment (LLG16) (Fig. 3d, lower panel), which, 
interestingly, corresponds to similar fragments previously characterized23 and generated by processing of cathel-
icidin by skin proteases32.
LL-37 effects on biofilm production. Although we could not find any substantial effect of LL-37 on erad-
ication of biofilm assessed by the Calgary Biofilm Device (CBD)-method, LL-37 might still have inhibitory effects 
on biofilm formation. To investigate this, an abiotic solid surface assay was performed as described by Hell et al.33, 
with minor modifications. The results showed that LL-37 concentrations above 20 μM significantly inhibited bio-
film formation of S. aureus isolates being high producers of biofilm (P < 0.05, Wilcoxon rank sum test), whereas 
no or little inhibitory effect was observed on low biofilm producing isolates, as well as the ATCC29213 strain 
(Supplementary Fig. S6a). The LL-37 derived fragments yielded no effects on biofilm formation at the same doses 
as used for LL-37 (Supplementary Fig. S6b). Moreover, S. aureus isolates were subjected to LL37 and FKR21 in 
low salt and physiologic salt conditions. The results showed that LL-37 was less inhibited by salt when compared 
to the results obtained with the peptide FKR21 (Supplementary Fig. S7).
Discussion
The main findings in this study are the identification of bacterial biofilm in lesions of S. aureus colonized AD skin 
combined with findings that S. aureus isolates of patients with AD are able to produce a substantial amount of 
biofilm, which in turn, may protect S. aureus from LL-37-mediated killing. Since biofilms are typical for later stage 
growth phases, our data correspond well with results showing that protease production of S. aureus reaches maxi-
mal activity in the post-exponential growth phase20. Our data also correspond well with recent reports identifying 
biofilms and glycocalyx structures on skin from AD patients, along with biofilm producing S. aureus isolates7, 9, 34. 
Taken together, all these observations, combined with the fact that staphopains are among the most copiously 
produced proteases of S. aureus20, 35, clearly motivate further studies on the clinical importance of biofilms for 
bacterial persistence and protease activity in patients with AD.
LL-37 is one of the most well characterized AMPs found in human skin particularly under inflammatory 
conditions, present in the specific granules of neutrophils and in keratinocytes36–38. The level and expression of 
LL-37 is reported to range from ≈1 μM in human sweat, to higher local concentrations in inflamed skin, such as 
in acne rosacea17, 18. S. aureus biofilms are composed of, not only bacteria, but also an extracellular matrix com-
prising multiple macromolecules, including polysaccharides (such as polysaccharide intercellular adhesin), extra-
cellular DNA and proteins39. It is therefore likely that interactions between biofilm substances such as negatively 
charged polysaccharides and LL-37 can lead to scavenging and inactivation of the peptide´s antimicrobial activity. 
Compatible with these observations are the findings with confocal microscopy, showing binding of LL-37 to the in 
vitro grown biofilm. It is also of note that at high concentrations, LL-37 showed inhibitory effects on biofilm for-
mation of S. aureus. Hence, our results correspond with earlier reports on LL-37 and biofilm formation, however, 
the effectiveness of LL-37 in disrupting S. aureus biofilm seems to be less in comparison to other peptides40, 41. 
Name Sequence Biological activity Reference
LL-37 LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES AM, AB, IM This paper23
LLG11 LLGDFFRKSK E NF This paper
LLG16 LLGDFFRKSK EKIGKE NF This paper23
LLG LLGDFFRKSK EKIGKEFKRI V AM, IM2 24
GKE GKEFKRI VQRIKDFLRN LVPR AM, IM1c,2 24
FKR10 FKRI VQRIKD NF This paper
FKR21 FKRI VQRIKDFLRN LVPRTES AM, IM1a,2 This paper24
FLR11 FLRN LVPRTES NF This paper
RK-31 RKSK EKIGKEFKRI VQRIKDFLRN LVPRTES AM, IM3 23, 25
KS-30 KSK EKIGKEFKRI VQRIKDFLRN LVPRTES AM, IM3,4 23, 25, 26
LL-31 LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN L IM1b,3 27
LL-25 LLGDFFRKSK EKIGKEFKRI VQRIK IM1b 27
RK-25 RKSK EKIGKEFKRI VQRIKDFLRN L IM1b,3 27
IG-25 IGKEFKRI VQRIKDFLRN LVPRTES IM1b,3 27
IG-19 IGKEFKRI VQRIKDFLRN L IM1b,2,5 27, 28
F106 GDFFRKSK EKIGKEFKRI VQRIKDFLRN LVPRTES AM, IM2 29
F110 RKSK EKIGKEFKRI VQRIKDFLRN LVPRTES AM, IM1c,2 29
Table 2. A selection of published peptide sequences derived from LL-37 with immune-modulating actions, and 
examples of their biological effects. IM, immune-modulatory effects: 1aReduced LPS or LTA induced NF-κΒ 
and AP-1 activation or 1bLPS binding, with implication to neutralize the LPS cytokine response, 1cInhibition 
of LPS-induced nitric oxide production, 2chemotactic activities on human neutrophils, 3inhibition of IL-8 
production, 4increased IFNs production from keratinocytes, 5abrogated IL-32γinduced TNF-α and IL-1β 
production in peripheral blood mononuclear cells (PBMC). AM, antimicrobial effects. AB, anti-biofilm effects. 
NF, no immune-modulating activity found. F, fragment.
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Although the exact mechanisms of how LL-37 performs its anti-biofilm effects are not fully elucidated, the central 
fragment of the peptide seems to be important for its anti-biofilm effects42.
The findings that S. aureus proteases from the biofilm, such as staphopains, were able to degrade LL-37, gener-
ating peptide fragments with modified or abrogated antibacterial effects on planktonic bacteria as well as bacterial 
biofilms, may have important implications. It has been previously reported that peptide fragments produced by 
degradation of LL-37 can exert pro-inflammatory actions in skin18. The degradation of LL-37 by staphopains 
may therefore yield comparable pro-inflammatory effects which in turn, might further amplify the inflammatory 
process and the “pathogenic vicious loop” typical for AD43. In our in vitro studies one of the low molecular weight 
peptide fragments produced by degradation of LL-37 (FKR21) was able to reduce TLR4- and TLR2-mediated 
responses, indicating that some fragments may have retained anti-inflammatory actions. Interestingly, a fragment 
produced by the staphopain SspB (LLG16), is almost identical to a fragment generated by processing of cathelici-
din by skin proteases (LL-17)32. This suggests a functional overlap between the activities of endogenous proteases 
such as kallikreins, and bacterial enzymes such as SspB. Furthermore, bacterial proteases found in biofilms can 
also provide a reservoir of enzymes, that directly activate proenzymes, such as kallikreins, or perhaps cleave struc-
tural proteins of importance for maintaining a permeability barrier44, 45.
As mentioned in the Introduction, staphylococci may influence various pathomechanisms in AD. The results 
by Allen et al.7 indicate that staphylococci may activate toll like receptor 2 (TLR2)7 and up-regulate the expression 
and production of several pro-inflammatory cytokines14. Even though it is reported that patients with AD show 
less response to TLR-2 stimulation than healthy controls46, several products from S. aureus are known to induce 
a pro-inflammatory response in keratinocytes47. Furthermore, superantigens from staphyloccoci may directly 
stimulate T-lymphocytes via the T-cell receptor48. It is also reported that protease production by S. aureus causes 
skin barrier dysfunction49 and that S. aureus colonization is associated with impairments of the skin barrier in 
AD4. Chronic biofilm infections by S. aureus can activate the immune system generating damage of host tissue, 
and therefore generate an environment facilitating the persistence of the biofilm50. Moreover, suppression of the 
inflammatory response seems to prevent the development of chronic biofilm infections51.
Biofilm production by staphylococci could constitute an overlooked pathogenic mechanism, leading to inac-
tivation of AMP-mediated bacterial killing. It is also notable that S. aureus derived proteases, such as staphopains 
(SspB and ScpA) are known to inhibit biofilm formation, and the addition of ScpA to bacterial biofilm was shown 
to be able to disperse an established biofilm52. Thus, under conditions with up-regulated staphopain production, 
these proteases may not only degrade endogenous AMPs, but also counteract biofilm formation and disperse the 
S. aureus biofilm. Whether this enables bacterial spread and skin infection under certain circumstances remains 
to be investigated.
In conclusion, our results demonstrate the existence of S. aureus biofilms and staphopains in AD skin. The 
biofilm protects the bacteria from LL-37 mediated killing, and further, staphopains may cleave LL-37 into smaller 
fragments. Biofilm formation by S. aureus strains could thus support a persistent bacterial colonization in AD 
skin. Moreover, S. aureus biofilms could be a source of proteolytic enzymes at the skin surface, with the capacity 
to cleave endogenous AMPs and interfering with the epidermal inflammatory response.
Methods
LL-37, peptides, SspB and ScpA. LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) was 
synthesized by Innovagen AB (Lund, Sweden). The peptides FKR10 (FKRIVQRIKD), FLR11 (FLRN LVPRTES), 
LLG11 (LLGDFFRKSKE) and FKR21 (FKRIVQRIKDFLRNLVPRTES) were synthetized by Biopeptide (San 
Diego, CA, USA). The purity of the peptides (>95%) was confirmed by mass spectroscopy analysis (MALDI-
TOF Voager). SspB was from Sigma-Aldrich. ScpA was from Preparatis (Krakow, Poland).
Patients and skin biopsy. Adult patients aged 18 years or over, with AD verified by the UK refinement 
of the Hanifin and Rajka diagnostic criteria for AD53, 54, were recruited from the Dermatology Clinic at Lund 
University Hospital, Lund, Sweden. Bacterial samples were taken from the skin of the patients and tissue biopsies 
from AD lesional areas were processed as per standard procedure, for description see section electron microscopy 
and immuno-staining. The participants gave informed consent complying with the Helsinki Declaration, all meth-
ods and experiments were performed in accordance with relevant guidelines and regulations, and the Regional 
Ethics Examination Board of Lund, Sweden approved the study (Permit Numbers: 144/2010, 317/2010, 82/2012).
Bacterial isolates. Staphylococcus aureus ATCC 29213 isolate was from the American Type Culture 
Collection (Rockville, MD, USA). Clinical bacterial flora specimens were obtained from the skin of AD patients 
using a modified version of a method described by Williamson and Kligman55. Briefly, a sterile plastic cylinder 
(3.8 sq cm) was applied to the area of the skin to be scrubbed. Then, a sterile solution of 1 ml 0.05% Triton X-100 
in 0.075 M phosphate buffer was pipetted into the plastic cylinder and the area scrubbed for 60 seconds with a 
sterile Servant® disposable inoculation loop and needle (Konstrumed oy, Tempere, Finland). For identification 
of bacteria, the samples were processed at the Department of Clinical Microbiology at Skåne University Hospital 
in Lund, Sweden, following standard routines for identification of S. aureus. Molecular typing was performed 
using ADSRRS-fingerprinting analysis as previously described56, 57. Briefly, DNA from S. aureus was digested with 
the two restriction enzymes BamHI (10 U/μl) (Sigma) and Xbal (10 U/μl) (Sigma). Cohesive ends of DNA were 
ligated with adapters and then amplified. The PCR products were electrophoresed on polyacrylamide gels and 
then stained with ethidium bromide. The gels were photographed under UV-light. The strains used in this study 
represent a variety of different genotypes (Supplementary Table S1).
Biofilm assay. Quantification of biofilm formation of S. aureus isolates was performed in a 96-well microtiter 
plate assay as previously described, with minor modifications58 (See Supplementary Methods S1).
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Abiotic solid surface assay (SSA) biofilm formation. To investigate the effect of LL-37 on the biofilm 
formation of S. aureus isolates, Abiotic SSA was performed as described by Hell et al.33 (See Supplementary 
Methods S1).
Minimum inhibitory concentration (MIC) and minimal biofilm eradication concentration 
(MBEC). Measurement of the bacterial susceptibility was determined by using a modified version of the CBD 
method (MBECTM Biofilm Inoculator, Innovotech, Edmonton, Canada)59 following the manufacturers protocol. 
Briefly, to establish biofilms in vitro using the CBD, 150 μl bacterial solution of 105 CFU/ml in 1.5% tryptic soy 
broth (TSB) was supplemented with 0.3% glucose and aliquoted into each well of the MBEC plate and thereafter 
incubated for 24 h in a rotary incubator at 37 °C and 180 rpm. This allowed the biofilm to form on the pegs. The 
pegs with established biofilms were then washed once in sterile PBS (200 μl/well). The LL-37 peptide was serially 
diluted in Müller Hinton broth (MHB) in a 96-well polypropylene microplate (Costar®, Corning, NY, USA) and 
incubated for 16 h according to the NCSLA guidelines, as described by Wiegand et al.60.
The MIC values measured using the CBD are equivalent to MIC values obtained using the National 
Committee for Clinical Laboratory Standards (NCCLS) procedure59. The MIC value, representing the concen-
tration required to inhibit growth of planktonic bacteria, was determined from bacteria that were shed from the 
pegs when the lid of the CBD was placed in different concentrations of LL-37. Following determination of the 
MICs for planktonic cells, the MBEC pegs were washed once in sterile PBS and placed into the recovery plate 
containing 1.5% TSB supplemented with 0.3% glucose and universal neutralizer following the manufacturers 
protocol (200 μl/well). The recovery plates were sonicated for 10 min at maximum settings in an ultrasonic bath 
(Elmasonic S 30 H, Elma Hans Schmidbauer GmbH & Co. KG, Singen, Germany), a new plate cover was then 
added. MBECs were determined by analyzing the bacterial viability in the biofilm after 24 h of incubation at 37 °C 
either by reading the turbidity at 600 nm in a 96-well plate reader (Victor3 1420 multilabel counter, Perkin-Elmer) 
or by obtaining bacterial plate counts. The recorded MIC and MBEC values represent a typical result of three 
independent experiments.
Radial diffusion assay (RDA). RDA was performed as previously described61, 62 (See Supplementary 
Methods S1).
Fluorescent staining and CLSM. Bacterial cell cultures of S. aureus isolates were suspended in 3% TSB and 
shaken at 180 rpm in an incubator at 37 °C for 18 h. A bacterial solution of 107 CFU/ml in 1.5% TSB supplemented 
with 0.3% glucose was prepared. In vitro biofilms were then established by adding 1 ml aliquots of the bacterial 
solution to sterile CellviewTM cell culture dishes with glass bottom (Greiner Bio-One, Germany), incubated at 
37 °C for indicated time periods, and the medium was changed every second day. The medium was removed and 
the culture dishes were gently washed using PBS solution. For CLMS, the remaining adherent microbial biofilms 
present on the bottom of the dishes were stained by adding 200 μl/dish of a dilution of 3 μl SYTO® 9 green flu-
orescent stain (Live/dead® BacLightTM bacterial viability kit L7012, Molecular Probes, USA) into 1 ml distilled 
water, and incubated at 37 °C for 15 min in the dark. Subsequently, the samples were incubated with 200 μl of 
5 μM TAMRA-labeled LL-37 (Innovagen AB, Lund, Sweden), followed by incubation at 37 °C for 15 min in the 
dark. The samples were then fixed with 2% freshly prepared formaldehyde solution and incubated for 5 min on 
ice followed by 25 min at room temperature. Subsequently, the material was mounted on glass coverslips using 
Dako fluorescent mounting medium (S3023, Dako Sweden AB, Stockholm, Sweden). After each step of staining 
and fixation the biofilm was gently washed twice with PBS. Images were captured using a Zeiss laser-scanning 
microscope 510 (Carl Zeiss, Jena, Germany). An objective lens (plan aperture, 20x magnification) was used. The 
image stacks collected by CLSM were analyzed or processed with Zeiss Efficient Navigation (ZEN) 2009 software 
(Carl Zeiss, Germany) and by the ImageJ software.
Electron microscopy and immuno-staining. Transmission immunoelectron microscopy was performed 
as described earlier63. In short, specimens were fixed in 150 mM sodium cacodylate, 2.5% glutaraldehyde, pH 7.4 
and embedded in Epon. After antigen retrieval with sodium metaperiodate, specimens were incubated with pri-
mary antibodies, followed by detection with species-specific secondary antibody-gold conjugates. Samples were 
examined in a Philips/FEI CM 100 TWIN transmission electron microscope (FEI Co, Hillsboro, Oregon, USA) 
at 60-kV accelerating voltage. Images were recorded with a side-mounted Olympus Veleta camera with a resolu-
tion of 2048 × 2048 pixels (2 k × 2 K) using ITEMTM software. For scanning electron microscopy, specimens were 
fixed over night at RT with 2.5% glutaraldehyde in 150 mM cacodylate, pH 7.4. After washing with cacodylate 
buffer, they were dehydrated with an ascending ethanol series from 50% (v/v) to absolute ethanol, and subjected 
to critical point drying with carbon dioxide. Tissue samples were mounted on aluminum holders, sputtered with 
20 nm palladium/gold, and examined in a Philips/FEI XL 30 FESEM scanning electron microscope using an 
Everhart-Tornley secondary electron detector or in DELPHI, Phenom-World. Image processing was done with 
the Scandium software for simple image acquiring and auto-storage into the Scandium database. All electron 
microscopic work was performed at the Core Facility for Integrated Microscopy, Panum Institute, University of 
Copenhagen and at Infection Medicine, Lund University. Contrast, brightness and pseudocolours were adjusted 
in Adobe Photoshop CS6.
Anti-ScpA and anti-SspB monoclonal antibodies. ScpA and SspB were isolated from the culture 
medium of the V8 strain of S. aureus or isogenic double sarA and scpA mutant of S. aureus 8325–4 deficient 
in ScpA and overexpressing SspB as described previously64, 65. Alternatively, prostaphopain B was cloned into 
pGEX-5T, expressed, processed by V8 protease and purified as described by Filipek et al.66. Anti-ScpA (IgG1, 
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1A3) and anti-SspB (5E12 and 13G12, all IgG1) monoclonal antibody (MAb) were produced in a monoclonal 
facility at the University of Georgia (Athens, GA).
Ex vivo model, quantification of strongly adherent bacteria in lesional AD skin (See Supplementary 
Methods S1).
NF-κB/AP-1 activation assay and MTT assay (See Supplementary Methods S1).
Proteolytic degradation of LL-37 and SDS-PAGE analysis (See Supplementary Methods S1).
Mass spectrometric identification of LL-37-derived peptides. Matrix-assisted laser desorption ion-
ization mass spectrometry (MALDI-MS) was used for the identification of trypsin generated peptides of LL-37. A 
MALDI matrix solution consisting of 5 mg/ml hydroxycinnamic acid in 50% acetonitrile, 0.1% (v/v) phosphoric 
acid67 was mixed with the staphopain-generated peptides. The matrix solution contained two peptide standards 
[des-arg-bradykinin (m/z 904.468) and ACTH 18–39 (m/z 2465.199)] that were used for internal mass calibra-
tion in every analyte/matrix position. MALDI-MS and MS/MS analyses of the samples were performed on a 
4700 Proteomics Analyzer MALDI-TOF/TOF™ mass spectrometer (Applied Biosystems, Framingham, MA). 
Database searching was carried out using Mascot (Matrix Science) with Swissprot as the database and with a 
peptide mass tolerance of 50 ppm and a fragment mass tolerance of 0.2 Da.
Statistics. Data are presented as means ± standard deviation of the means. To describe the differences 
between groups, one-way ANOVA with Dunnet’s multiple comparisons test was used. In order to determine 
significant differences between two groups, the Wilcoxon rank-sum test was used, and p < 0.05 was considered as 
significant. The statistical software used was GraphPad PRISM® version 6.0c (GraphPad Software, Inc., La Jolla, 
CA, USA).
Data Availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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